LUCA Science Inc.
Yoshikazu Tokuoka currently serves as Chief Financial Officer at LUCA Science Inc. since March 2021. Previously, Tokuoka held the position of Director at PricewaterhouseCoopers LLP from October 2006 to September 2015, where responsibilities included managing data management services to enhance financial reporting accuracy and efficiency for Financial Services clients under various regulatory frameworks. Prior to that, Tokuoka worked as a Senior Manager at KPMG LLP from July 1998 to September 2006, providing assurance services and financial due diligence to a diverse range of financial institutions. Tokuoka earned a Bachelor of Science degree in Accounting and Finance from Purdue University between 1994 and 1998.
This person is not in any offices
LUCA Science Inc.
LUCA Science is at the forefront of a new kind of mitochondrial therapy that aims to restore cellular bioenergetics in malfunctioning or damaged tissues and organs. Using our patented iMIT technology, LUCA Science is creating a novel platform of highly functional mitochondria. We could boost bioenergetics and restore normal activities by supplyingintact and functional mitochondria to the affected tissues. The utilization of mitochondria as a biopharmaceutical agent would be groundbreaking for treating a wide range of unmet medical needs.